Sanofi (SNY,SNYNF,SAN.PA) announced positive topline results from the global Phase 2 ElevAATe study evaluating efdoralprin alfa (SAR447537, formerly INBRX-101) in adults with alpha-1 antitrypsin deficiency (AATD) emphysema. The investigational recombinant human AAT-Fc fusion protein met all primary and key secondary endpoints when administered every three weeks (Q3W) or four weeks (Q4W).
Efdoralprin alfa demonstrated a statistically significant greater mean increase in functional AAT (fAAT) levels within the normal range, as measured by trough concentrations at steady state, compared to weekly plasma-derived augmentation therapy at week 32 (p<0.0001). Key secondary endpoints were also met, including superior mean fAAT average concentration and a higher percentage of days above the lower limit of the normal range for both dosing regimens.
The therapy was well tolerated, with an adverse event profile comparable to plasma-derived therapy. Additional safety data will be collected in the ongoing ElevAATe OLE Phase 2 extension study.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.